American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic

by admin June 27, 2024
June 27, 2024
Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic

Novo Nordisk on Monday said it will spend $4.1 billion to build a new manufacturing plant in Clayton, North Carolina, in a bid to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies. 

Demand for Wegovy and Ozempic has outstripped supply over the last year, spurring intermittent shortages in the U.S. and forcing the Danish drugmaker to invest heavily to increase its manufacturing footprint. The company said it plans to invest $6.8 billion in production this year, up from roughly $4 billion last year. 

The new manufacturing facility will be responsible for filling and packaging syringes and injection pens for the drugs, according to a company release. 

An Ozempic injection pen.David J. Phillip / AP

“This investment really gives us the opportunity to serve more patients,” Doug Langa, Novo Nordisk’s head of North American operations, said in an interview. “Importantly, I think the other key message here is it’s further investment in the U.S., so I think we’re very proud of that.”

Construction of the 1.4 million-square-foot facility has begun and is expected to be completed between 2027 and 2029, Novo Nordisk said. The company said 1,000 workers will staff the site, adding to the 2,500 employees already working at its three existing manufacturing plants in North Carolina. 

That includes two sites that are already operational in Clayton — one responsible for fill and finish work and another dedicated to producing the active ingredient in the company’s diabetes pill Rybelsus. The company also has a site in Durham, North Carolina, responsible for manufacturing and packaging oral drugs and another facility in West Lebanon, New Hampshire.

Twelve other production sites are located in Denmark, France, China, Japan, Algeria, Brazil, Iran and Russia, according to a Novo Nordisk spokesperson.

Three lower doses of Wegovy are currently in shortage in the U.S. due to high demand, according to a Food and Drug Administration database. Patients start Wegovy with lower doses and gradually increase the amount every four weeks until they reach a target dosage.

Wegovy is an injectable prescription weight loss medicine. Michael Siluk / Universal Images Group via Getty Images

Wegovy and Ozempic are part of a class of medications called GLP-1s that mimic hormones produced in the gut to suppress a person’s appetite and regulate their blood sugar.

Around 35,000 U.S. patients on average start Wegovy each week today, up from roughly 27,000 in May, a Novo Nordisk spokesperson said in a statement. Still, Langa said the company is being “very purposeful” about how many lower doses it is releasing into the U.S. market to ensure patients who have already started taking Wegovy can continue treatment with higher doses.

Rival drugmaker Eli Lilly has also committed billions of dollars to increase manufacturing capacity for its popular GLP-1s for weight loss and diabetes, Zepbound and Mounjaro. The company similarly has several production plants in North Carolina. 

This post appeared first on NBC NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
Antisemitism group calls on Biden to fire official who posted, deleted anti-Israel tweets: ‘just horrifying’
next post
Treasury Secretary Yellen announces $100M affordable housing fund as shelter costs weigh on Biden

Related Posts

Sensex and Nifty rise, tracking Asian market cues;...

December 3, 2024

Lloyds share price technical analysis: can it keep...

March 26, 2025

Chipotle stock price double-top points to a crash...

April 21, 2025

Who is Tracy Morgan? The comedian with a...

March 18, 2025

What American Express earnings reveal about US consumer...

January 25, 2025

Futu Holdings stock: is it safe to buy...

October 1, 2024

Morgan Stanley stock sits at record high: buy,...

October 25, 2024

Indian markets open: Sensex, Nifty retreat after record...

April 16, 2025

Will scrutiny around “tax dodges” and alleged labour...

September 28, 2024

Asian markets open: stocks fall, Kospi drops 2.3%;...

August 1, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • How Donald Trump’s immigration crackdown may tank the labor market

      August 4, 2025
    • Trump’s tariff threat looms over India’s Russian oil deals

      August 4, 2025
    • Trump moves nuclear submarines near Russia: what triggered the move and what’s ahead

      August 3, 2025
    • BOE rate cuts offer little relief as UK households face mounting financial strain

      August 3, 2025
    • Retail investors shift focus to Europe as US valuations stretch

      August 3, 2025

    Categories

    • Business (3,583)
    • Investing (2,703)
    • Latest News (2,031)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved